The QualityStocks Daily Friday, September 6th, 2019

Today's Top 3 Investment Newsletters

Penny Stock Titans (DUUO) +542.86%

QualityStocks (RSPI) +88.89%

StockMarketWatch (MBOT) +44.08%

The QualityStocks Daily Stock List

Blue Moon Zinc Corp. (BMOOF)

NetworkNewsWire, Junior Mining Network, Market Screener, Mining.com, Gold Telegraph, Stockwatch, Wallet Investor, Morningstar, Stockhouse, Small Cap Power, StreetWise Reports, Geology for Investors, Stock Pulse, Metals News, TradingView, and Dividend Investor reported previously on Blue Moon Zinc Corp. (BMOOF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Blue Moon Zinc Corp. engages in the exploration and development of mineral resource properties in the United States. Currently, the Company is advancing its 100 percent-controlled Blue Moon zinc deposit that also contains copper, gold, and silver. The Company formerly went by the name Savant Explorations Ltd. It changed its corporate name to Blue Moon Zinc Corp. in July of 2017. Incorporated in 2007, Blue Moon Zinc has its head office in Vancouver, British Columbia. The Company lists on the OTC Markets.

The Company’s advanced stage Blue Moon project is subject to an NI 43-101 Mineral Resource estimate with about 7.8 million tons with a grade of 8.07 percent zinc equivalent for approximately 771 million pounds of zinc, 71 million pounds of copper, 300,000 ounces of gold and 10 million ounces of silver in the Inferred category. The resource is open at depth and along strike and has favorable metallurgy. Blue Moon Zinc’s plan is to advance the project to feasibility and permitting. The Blue Moon Deposit is in east central California within Mariposa County in the Foothills.

Additionally, Blue Moon Zinc has its Yava Property in the Mackenzie Mining District, Territory of Nunavut, roughly 450 kilometers northeast of Yellowknife. Yava encompasses four known base and precious metal occurrences mid-way along the length of this greenstone belt.

The Yava mining lease includes 9 km of northwest-trending strike-length along a volcanic-sedimentary rock interface. Three of the mineral claims at the Yava Property are contiguous with the mining lease. They cover this strike-length for 2.5 km to the southeast. Five of the mineral claims encompass, though not continuously, a 25 km northwest extension of this strike-length. The other eight mineral claims cover volcanic rocks in the footwall of the volcanic-sedimentary rock interface.

Last week, Blue Moon Zinc announced the signing of a strategic joint venture (JV) where Platina Resources, Inc. (PGM.AX) can earn a 70 percent interest in the Blue Moon polymetallic zinc-gold-copper-silver project. Platina Resources can earn an initial 50 percent interest (Stage 1) in the Blue Moon property by spending $3.0 million within eighteen months. This will include a minimum of 10,000 meters of drilling and metallurgical test work.

Upon Platina Resources earning its initial 50 percent interest in Stage 1, Platina has 30 days in which to elect to earn an additional 20 percent interest (Stage 2) in the Blue Moon property by spending $3.75 million within eighteen months. This will include the completion of a pre-feasibility study (FS) and also continued drilling, metallurgical test work, and environmental and permitting.

Blue Moon Zinc Corp. (BMOOF), closed Friday's trading session at $0.028, even for the day. The average volume for the last 3 months is 9,271 and the stock's 52-week low/high is $0.009999999/$0.058499999.

chart

Cyber Security 1 AB (CYBNY)

Stockhouse, GlobeNewswire, Seeking Alpha, TradingView, Morningstar, TeleTrader, Dividend Investor, 4-Traders, YCharts, and GuruFocus reported earlier on Cyber Security 1 AB (CYBNY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Cyber Security 1 AB is an international leader in Cyber Security. The Company provides cyber resilience solutions and conducts its operations through physical presences in Sweden, South Africa, the United Kingdom (UK), Kenya, Germany, Austria, Turkey, Greece, Italy, the Ukraine and the United Arab Emirates (UAE). The Company formerly went by the name Cognosec AB (publ). It changed its name to Cyber Security 1 AB in July of 2018. Cyber Security 1 AB is based in Stockholm, Sweden. The Company lists on the OTC Markets Group’s OTCQX.

Providing governance, risk, and compliance cybersecurity solutions, Cyber Security 1 provides solutions for client and information systems audit, penetration testing, application security assessment, and security monitoring. In addition, the Company provides solutions for urgent incident response and crisis management, data leakage and loss prevention, and network security and management. Cyber Security 1 has a growing international footprint, an impressive client list, a flourishing mergers and acquisition (M&A) strategy and in 2019 a newly appointed Chief Executive Officer (CEO). Furthermore, Cyber Security 1 had revenues of 44.54m EUR in 2018 and employed 239 personnel at the end of Q4 2018.

Cyber Security 1 announced earlier this year an exclusive five-year partnership with Formula 1®, the world’s premier motorsport series. It will provide Formula 1® with an assortment of resilient solutions, designed to enhance and secure Formula 1’s infrastructure from potential cyber threats. Cyber Security 1 will work closely with the Information Technology (IT) department at Formula 1®, delivering a number of key projects. This includes consultancy, implementation, and advisory.

Cyber Security 1 announced this past March the signing of exclusive Heads of Terms of Agreement pursuant to the acquisition of IntaForensics. Since IntaForensics’ formation in 2006, the business has grown worldwide to provide the widest variety of Digital Forensic and Cyber Security Services from its England headquarters.

IntaForensics is one of the fastest growing Digital Forensic Services providers globally. It is one of a few organizations that possesses the prestigious ISO/IEC 17025 Laboratory Standard. Additionally, it is accredited to ISO/IEC 27001 and ISO 9001. The business is accredited by the PCI Security Standards Council as a Qualified Security Assessor and a PCI Forensics Investigator (QSA, PFI).

Last month, Cyber Security 1 reported its H1 2019 results. Selected highlights include Total Revenue growth increasing by 267.7 percent, from 9.01m EUR H1 2018, to 33.13m EUR H1 2019. Organic Revenue (excluding 2018 acquisitions) rose by 121 percent, from 9.01m EUR H1 2018, to 19.91m EUR H1 2019. Group Gross Margin rose 86.8 percent, from 3.71m EUR H1 2018, to 6.93m EUR in H1 2019.

Cyber Security 1 AB (CYBNY), closed Friday's trading session at $1.50, even for the day. The average volume for the last 3 months is 90 and the stock's 52-week low/high is $1.21000003/$3.86999988.

chart

DionyMed Brands, Inc. (DYMEF)

SmallCapPower, OTC Markets, Investors Hangout, Stockwatch, Penny Stock Hub, InvestorX, Business Wire, Otc.watch, Trading View, New Cannabis Ventures, Dividend Investor, Stockhouse, and GuruFocus reported earlier on Chemesis International, Inc. (DYMEF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, DionyMed Brands, Inc. is a multi-state cannabis brands and distribution platform. The Company supports cultivators, manufacturers, and award-winning brands in the medical and adult-use cannabis markets. DionyMed sells branded products in every category from flower to vape cartridges, concentrates and edibles. The Company’s brands include Winberry Farms, Gardener’s, Aja, and Afterglow. Its portfolio brands include Herbology, Fire King, Headwaters, HigherVeda Medicinals, GPen, Reveur, and Gio. Formed in 2017, DionyMed Brands has its corporate office in Toronto, Ontario.

DionyMed Brands serves cannabis consumers through retail dispensary distribution and direct-to-consumer fulfillment with its growing portfolio of award-winning brands. The Company has 12 wholly-owned brands. It serves greater than 800 dispensaries monthly. In addition, DionyMed performs 1,500 Direct-to-Consumer Deliveries per day.

DionyMed has an expertly designed proprietary platform. This platform supports the design, development, distribution, and marketing of award-winning brands at scale. Concerning its brands, the Company has a growing product portfolio leveraging important market opportunities to develop leading brands.

Pertaining to distribution, DionyMed has an industry-leading platform empowering end-to-end compliant delivery, sales and cash logistics for brands, cultivators, and retailers. Additionally, DionyMed is the largest Direct-to-Consumer fulfillment provider and has an extensible platform for D2C e-commerce. Its services include Logistics Services & Software; Warehousing & Co-Packing; Value-Added Manufacturing; and Retail & Direct-to-Consumer Delivery.

This past June, DionyMed Brands announced that it entered into an investment agreement with Alumina Partners (Ontario) Ltd. providing availability of up to CAD$32 million over a 24-month period, to provide funding for the expansion of the Company’s leading cannabis product portfolio into new growth markets. With this Agreement, DionyMed will sell, on a private placement basis completed in tranches, units of the Company with a total value of up to CAD$2 million per tranche, over a 24-month period.

Last week, DionyMed Brands announced its financial and operational results for its Q2 ended June 30, 2019. It generated $12.7 million and $34.4 million Total Gross Revenue (including the value of all product processed) during the three and six months ended June 30, 2019.

Moreover, DionyMed expanded the “Chill” Direct-to-Consumer delivery platform with 950 percent order growth during Q2 sequentially over Q1, which at the end of June 2019 was operating at a current $10.3 million annualized run-rate delivering to 14 cities in the Bay Area. For the year to date, the Company delivered or sold products to 441 out of 624 active retail dispensaries in California and 387 out of over 600 active retail dispensaries in Oregon.

Chemesis International, Inc. (DYMEF), closed Friday's trading session at $0.88, up 14.2857%, on 83,995 volume with 94 trades. The average volume for the last 3 months is 87,585 and the stock's 52-week low/high is $0.620000004/$3.21000003.

chart

Harvest Health & Recreation, Inc. (HRVSF)

Cannabis Stock Trades, Profit Confidential, Micro Cap Daily, New Cannabis Ventures, Stockhouse, Proactive Investors, InvestorsHub, Midas Letter, and Market Watch reported beforehand on Harvest Health & Recreation, Inc. (HRVSF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Harvest Health & Recreation, Inc. is a vertically-integrated cannabis company and has one of the largest and deepest footprints in the United States. The Company is a multi-state cannabis operator (MSO). Its mission is to improve lives through the goodness of cannabis. Harvest Health & Recreation is centered on its vision to become the most valuable cannabis company globally. The Company has its head office in Tempe, Arizona. Harvest Health & Recreation lists on the OTC Markets’ OTCQX.

The Company’s total vertical solution includes industry-leading cultivation, manufacturing, and retail facilities, construction, real estate, technology and operational expertise - leveraging in-house legal, human resources and marketing teams, along with proven experts in writing and winning State-based applications. Its commitment since 20111 has been to aggressively expanding its Harvest House of Cannabis retail and wholesale presence across the United States acquiring, creating and growing top brands for patients and consumers nationally, and continuing on a path of profitable growth.

Subject to the completion of announced acquisitions, Harvest Health & Recreation will have the largest footprint in the United States with rights to 210 facilities, of which 140 are retail locations and more than 1,580 employees across 17 States. Harvest Health & Recreation currently operates or has rights to operate in cannabis facilities or expects to have rights to acquire licenses following the closings of earlier announced acquisitions in Arizona, Arkansas, California, Delaware, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, Nevada, North Dakota, Ohio, Oklahoma, Pennsylvania and Puerto Rico.

In April of this year, Harvest Health & Recreation announced that it entered into a binding, definitive agreement to acquire CannaPharmacy, Inc., subject to satisfaction of customary closing conditions. This includes receipt of regulatory approvals in the relevant States. CannaPharmacy owns or operates (through management companies) cannabis licenses in Pennsylvania, Delaware, New Jersey, and Maryland. In addition, it holds a minority interest in a pending licensee in Colombia.

This past June, Harvest Health & Recreation announced the results of its June 26, 2019 annual general and special meeting of Harvest shareholders held to approve, among other things, certain matters relating to the Company’s earlier announced definitive agreement for its acquisition of Verano Holdings, LLC. Furthermore, the members of Verano approved the Transaction overwhelmingly with 100 percent of the votes cast at a special meeting of its members on June 26, 2019.

Last week, Harvest Health & Recreation announced it will now offer new premium-quality products from Cookies, a foremost lifestyle and cannabis brand in North America, at select Harvest medical dispensaries throughout Arizona. Starting August 30, the new Cookies’ products, produced in Arizona and brought to market by Harvest Health & Recreation, will be available in limited quantities at select Harvest House of Cannabis stores.

Cookies is one of the most respected and top-selling cannabis brands in California, with more than 50 cannabis varieties and product lines. These include indoor, outdoor and sun-grown flower, pre-rolls, gel caps and vape carts.

Harvest Health & Recreation, Inc. (HRVSF), closed Friday's trading session at $5.47314, up 1.055%, on 257,408 volume with 562 trades. The average volume for the last 3 months is 322,652 and the stock's 52-week low/high is $0.100000001/$10.8510999.

chart

ImageWare Systems, Inc. (IWSY)

Zacks, Market Screener, Insider Tracking, Street Insider, Wallet Investor, MarketBeat, Simply Wall St, InvestorsHub, Wallmine, 4-Traders, Stockopedia, TipRanks, Super Stock Screener, Equity Clock, and Insider Financial reported beforehand on ImageWare Systems, Inc. (IWSY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ImageWare Systems, Inc. is a leader in mobile and cloud-based, multi-modal biometric identity management solutions. It provides two-factor, biometric and multi-factor cloud-based authentication solutions for the enterprise. ImageWare serves healthcare, banking, retail/e-commerce, government, and law enforcement and public safety markets. OTCQB-listed, ImageWare Systems is based in San Diego, California. The Company also has offices in Oregon, Canada, Mexico, and Japan.

ImageWare Systems delivers next-generation biometrics as an interactive and scalable cloud-based solution. It brings together cloud and mobile technology to provide two-factor, biometric, and multi-factor authentication for smartphone users, for the enterprise, and across industries. Its products support multi-modal biometric authentication including, but not limited to, face, voice, fingerprint, iris, palm, and more.

All of the biometrics can be combined with or used as replacements for authentication and access control tools (including tokens, digital certificates, passwords, and PINS) to provide the supreme level of assurance, accountability, and user-friendliness for corporate networks, web applications, mobile devices, and PC (Personal Computer) desktop environments.

ImageWare Systems has introduced the ImageWare Digital Identity Platform ™. This is an end-to-end digital biometric identity proofing, authentication and lifecycle management solution. The platform provides the broadest set of identity validation and biometric authentication capabilities in the industry.

Recently, ImageWare® Systems announced the integration of the Biointellic™ Intelligent Anti-spoofing System into its existing Digital Identity Platform. This enhancement enables businesses to further increase the security of their systems without increasing friction. The business benefits include mitigating the risk of expensive identity fraud and data breaches, without impacting user adoption and abandonment rates.

Mr. David Harding, Chief Technology Officer at ImageWare Systems, said, “With increased demand from IT security professionals, and businesses in general, for true identity authentication, biometric authentication systems must be strengthened with anti-spoofing capabilities. Passwords can be easily compromised, 2FA can be phished, and facial biometrics can be spoofed. Only intelligent anti-spoofing, combined with identity proofing and biometric authentication, enable enterprises to ensure true user identity.”

ImageWare Systems, Inc. (IWSY), closed Friday's trading session at $0.5288, up 5.76%, on 39,600 volume with 15 trades. The average volume for the last 3 months is 143,264 and the stock's 52-week low/high is $0.469999998/$1.79999995.

chart

Medicure, Inc. (MCUJF)

Zacks, MacroTrends, Stockhouse, Stock Earnings, Barchart, Private Capital Journal, Stockwatch, Streetwise Reports, Wallet Investor, Morningstar, MarketBeat, StockScores, and Investing.com reported earlier on Medicure, Inc. (MCUJF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A pharmaceutical company, Medicure, Inc. centers on the development and commercialization of therapies for the U.S. cardiovascular market. Its present focus is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they sell through the Company's U.S. subsidiary, Medicure Pharma, Inc. Established in 1997, Medicure is based in Winnipeg, Manitoba. The Company lists on the OTC Markets.

Medicure is a U.S focused Specialty Pharma company with established sales of Aggrastat. It carefully monitors opportunities within its own pipeline of products and possible acquisitions of related pharmaceutical companies to realize long term value. The Company’s subsidiaries include Medicure International, Inc. (Barbados), which owns the U.S. rights to AGGRASTAT, and also two U.S. corporations, Medicure USA, Inc. and Medicure Pharma, Inc., which distribute its products in the United States.

Recently, Medicure reported its results from operations for the quarter ended June 30, 2019. The Company recorded Net Revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $6.2 million during the quarter ended June 30, 2019 versus $7.2 million for the quarter ended June 30, 2018 and $4.8 million for the quarter ended March 31, 2019.

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) for the quarter ended June 30, 2019 was $103,000 versus adjusted EBITDA of $882,000 for the quarter ended June 30, 2018. Net Loss for the quarter ended June 30, 2019 was $957,000 (of which, $813,000 was because of a loss from foreign exchange) versus Net Income of $1.6 million for the quarter ended June 30, 2018. Net Loss for the three months ended June 30, 2019 is the result of lower Revenues experienced during the quarter and a foreign exchange loss relating to a drop in the value of the U.S. dollar experienced during the quarter ended June 30, 2019.

Medicure, Inc. (MCUJF), closed Friday's trading session at $3.35, even for the day. The average volume for the last 3 months is 462 and the stock's 52-week low/high is $3.04130005/$5.52390003.

chart

Rise Gold Corp. (RYES)

Geology for Investors, 24hgold, Streetwise Reports, Junior Mining Network, Newsfile, Pinnacle Digest, Infront Analytics, Wallet Investor, InvestorsHub, Stockwatch, Simply Wall St, The Prospector News, Stockhouse, Metals News, Market Screener, Infront Analytics, Dividend Investor, MarketBeat, Investor Ideas, and Stockopedia reported earlier on Rise Gold Corp. (RYES), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

An exploration-stage mining company, Rise Gold Corp.’s principal asset is the historic past-producing Idaho-Maryland Gold Mine situated in Nevada County, California. The gold-quartz mines of the Grass Valley-Nevada City District in Nevada County have been the most productive in California. The Idaho-Maryland Gold Mine was a major past producer, yielding 2,414,000 oz of gold at an average mill head grade of 17 gpt gold from 1866-1955.

The Company formerly went by the name Rise Resources, Inc. It changed its name to Rise Gold Corp. in April of 2017. Established in 2007, Rise Gold is based in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

There are numerous exploration targets on this property that is fully owned by Rise Gold. This includes surface and mineral rights. The Company has 100 percent ownership on what is private land (2,800 acres of subsurface land; 175 acres of industrial land). The property has all the mineral rights of the historic Idaho-Maryland Mine and there are no royalties on future gold production. The Idaho-Maryland Gold Mine features advanced targets with known mineralization.

Rise Gold announced this past June the successful completion of the initial surface exploration drilling program, the estimation of a significant Initial Exploration Target based on recent exploration drilling, and its strategy to advance the Idaho-Maryland (I-M) Gold Project towards the re-opening of the mine. Rise completed 19 drill holes, totalling 20,584 meters, over the past 20 months in its initial surface exploration drilling program at the I-M Gold Project.

Drilling confirmed the presence of significant extensions of earlier mined veins and structures. Many high-grade gold intercepts were encountered near the existing mine workings and to depths of greater than 1 km below historic mining areas.

Rise Gold previously announced that Mr. Lawrence Lepard was appointed as a Director of the Company. Mr. Lepard runs Equity Management Associates, LLC (EMA). This is an investment partnership that has concentrated on investing in precious metals since 2008. Before EMA, Mr. Lepard spent 25 years as a professional investor and venture capitalist.

Recently, Rise Gold announced that it closed the US$1 M debt financing with Eridanus Capital, LLC earlier announced in its August 20, 2019 news release. Eridanus Capital is an affiliate of Myrmikan Capital, LLC, which operates in the gold and silver junior mining sector. The Loan Principal of US$1,000,000 may be used for engineering, permitting, as well as working capital at the Idaho-Maryland Gold Project. It is secured against the assets of Rise Gold.

Rise Gold Corp. (RYES), closed Friday's trading session at $0.061, up 17.0556%, on 92,227 volume with 4 trades. The average volume for the last 3 months is 249,849 and the stock's 52-week low/high is $0.035100001/$0.100000001.

chart

H/Cell Energy Corporation (HCCC)

Financial Buzz, OTC Markets, Street Insider, Morningstar 4-Traders, Stockwatch, Uptick Newswire, Marketbeat, Market Screener, Simply Wall St, Stockhouse, and Wallet Investor reported previously on H/Cell Energy Corporation (HCCC), and we also report on the Company, here at the QualityStocks Daily Newsletter.

H/Cell Energy Corporation designs and implements clean energy solutions featuring hydrogen and fuel cell technology. The Company is an integrator that centers on the design and implementation of clean energy solutions. This includes solar, battery, fuel cell and hydrogen generation systems. By way of its subsidiaries, it also provides environmental systems and security systems integration. OTCQB-listed, H/Cell Energy is based in Dallas, Texas.

H/Cell serves the residential, commercial, as well as government sectors. It has developed and implemented a hydrogen energy system used to completely power a residence or commercial property with clean energy. This is so it can run independent of the utility grid and also provide energy to the utility grid for monetary credits. This inventive system utilizes renewable energy as its source for hydrogen production.

The HC-1 system is totally scalable. Upon installation, the HC-1 system operates as a self-sustaining energy system providing electricity and/or hydrogen fuel for transportation.

The design of the HC-1 system is to provide clean energy for a better environment. The system eliminates the electric bill and dependence on fossil fuels. Furthermore, this system allows one to benefit with tax and energy credits while helping make the environment safe for future generations. H/Cell Energy’s completed systems include the De Tiberge Property in Pennington, New Jersey and the Strizki Property in Hopewell, New Jersey.

Recently, H/Cell Energy announced that it entered into an equity purchase agreement with GHS Investments LLC (GHS). This agreement will provide the Company access to capital over a 24 month period.

Mr. Andrew Hidalgo, H/Cell Energy Chief Executive Officer, said, "We are very pleased to come to terms with GHS. We have reviewed many proposals for equity investments over the last year, most of which were unsuitable. However, we found GHS to be professional, competent and flexible in constructing an equity investment arrangement that we believe is beneficial to our shareholders. We intend to use any proceeds for growth initiatives as we continue to focus on building shareholder value.”

H/Cell Energy Corporation (HCCC), closed Friday's trading session at $0.60, up 50.00%, on 1,625 volume with 2 trades. The average volume for the last 3 months is 571 and the stock's 52-week low/high is $0.400000005/$1.60000002.

chart

EOS, Inc. (EOSS)

OTC Markets Group, InvestorsHub, MarketWatch, Investor Place, Stock Gumshoe, Zacks, Dividend Investor, Morningstar, Talk Markets, Streetwise Reports, 4-Traders, Wallet Investor, GuruFoucs, YCharts, and Stockhouse reported previously on EOS, Inc. (EOSS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

EOS, Inc. has a broad distribution network of associates with many dealer companies providing health care, beauty care, and environmentally friendly cleaning products in Asia. Since Q1 of 2017, the Company has expanded its marketing channels in China and Southeast Asian countries. Formed in 2015 and OTCQB-listed, EOS is headquartered in Taipei, Taiwan.

The Company previously acquired all of the issued and outstanding shares of Emperor Star International Trade Co. Ltd. (effective May 3, 2017). This is the trading team that plays a vital part in the supply chain of EOS products. EOS acquired Emperor Star trading company in Taipei, Taiwan to strengthen its business and prepare for the challenge of OBOR (One Belt and One Road) development in Malaysia, Indonesia, Thailand, and Cambodia. Emperor Star has been distributing highly unique health and beauty care products and environmentally friendly cleaning products, with first-rate growth in China and Asia.

EOS focuses on the marketing and distribution of skin care products to resellers in Taiwan. It engages in the distribution and marketing of skin care products manufactured by A.C. (USA), Inc. Its products include moisturizers, serums, cleansers, and toners. Products also include exfoliators, acne and oil correctors, facial masks, cleansing devices, and sun care products.

In 2017, Mr. Ben Yang, the chief representative of Asian market, EOS, Inc., signed agency contracts in Nanning City, Guangxi, China, with three owners of new flagship stores launched there. There are four flagship stores set up in China. This includes the first one in Quanzhou. This will help contribute to growing the business of EOS in China. Nanning City is the largest economy of Guangxi province.

On November 30, 2018, EOS signed a contract with A-Best Company and commenced to march toward the worldwide 3C market. A-Best Company is a foremost manufacturer of advanced Piezoelectric Ceramic Speakers.

The collaboration contract was signed by Mr. Yang He-Hsiang, President of EOS, and Mr. Lai Ying-Min, President of A-Best Wire Harness & Components Co., Ltd., at Gloria Prince Hotel in Taipei, Taiwan. The focus of this collaboration is on promoting A-Best Company's patented products, Piezoelectric Ceramic Speakers, and developing more value added products to the international 3C market.

EOS, Inc. (EOSS), closed Friday's trading session at $1.60, up 39.1304%, on 100 volume with 1 trade. The average volume for the last 3 months is 361 and the stock's 52-week low/high is $0.550000011/$3.50.

chart

RespireRx Pharmaceuticals, Inc. (RSPI)

NetworkNewsWire, Penny Stock Tweets, Infront Analytics, Stockflare, Barchart, InvestorsHub, Stockopedia, Penny Stock Hub, Wallet Investor, Simply Wall St, Marketbeat, YCharts, Street Insider, Marketwired, Stockhouse, Daily Marijuana Observer, last10k, Investors Hangout, GuruFocus, MarketWatch, Stockwatch, 4-Traders, and Real Investment Advice reported earlier on RespireRx Pharmaceuticals, Inc. (RSPI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders and CNS indications, with a concentration on obstructive sleep apnea, attention deficit hyperactivity disorder (ADHD), spinal cord injury, other neurological conditions and drug-induced respiratory depression. RespireRx Pharmaceuticals has its corporate office in Glen Rock, New Jersey. The Company lists on the OTC Markets Group’s OTCQB.

RespireRx has filed over 400 patents in the U.S. and offshore that claim composition of matter, use, formulation, dosage, as well as mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system (CNS) indications.    

The Company’s pharmaceutical candidates in development are derived from two platforms. One platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol. Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. Dronabinol (D9-THC) is a generic, orally active cannabinoid. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA).

RespireRx Pharmaceuticals (under a license agreement with the University of Illinois) has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders. Two Phase 2 clinical trials have been completed. Both have demonstrated substantial reductions in sleep apnea produced by dronabinol. 

Dronabinol is Food and Drug Administration (FDA) approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®). It is a Schedule III drug available by prescription, with a low risk of addiction.

The other platform of medicines undergoing development by RespireRx is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. Several ampakines, in oral and injectable form, are undergoing development by RespireRx for the treatment of an assortment of breathing disorders.

Recently, RespireRx Pharmaceuticals announcd the promotion of Mr. James Sapirstein to Executive Vice Chairman of the Board of Directors effective December 28, 2018. Mr. Sapirstein has served as a member of the Board of Directors since 2014. He expands his role within RespireRx Pharmaceuticals to assist with business development and fundraising activities to advance the development of the Company’s pipeline of neuromodulators with an emphasis on sleep apnea and neurologic and psychiatric disorders.

Mr. Sapirstein is a highly-regarded pharmaceutical industry executive. He has more than 35 years of success in building companies and leading the commercial launch of almost two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. Mr. Sapirstein has worked at major pharmaceutical companies, Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly. He has also led commercial teams for biotechnology companies including Gilead Sciences and Serono Laboratories.

RespireRx Pharmaceuticals, Inc. (RSPI), closed Friday's trading session at $0.85, up 88.8889%, on 830 volume with 5 trades. The average volume for the last 3 months is 75 and the stock's 52-week low/high is $0.222000002/$1.13999998.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stock Target Advisor, Stockopedia, Investors Hangout, Penny Stock Hub, Stockwatch, Simply Wall St, Zacks, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stockflare, and Dividend Investor reported on AEON Global Health Corp. (AGHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AEON Global Health Corp., together with its subsidiaries, provides a variety of clinical laboratory testing services in the United States. The Company provides diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, as well as Health Technology Applications. AEON formerly went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. in January 2018. OTCQB-listed, AEON Global Health has its corporate office in Gainesville, Georgia.

The Company is the fastest growing clinical lab and healthcare services organization in the United States. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results. AEON’s chief business focus is providing a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information.

AEON is an innovator in the genomic testing area. The Company has an extensive menu of genetic tests and a pipeline of additional molecular-based tests in development. It provides post contract customer support services. The design of AEON’s Telehealth Solutions is to improve outcomes and reduce hospital readmission through helping clinicians closely monitor patients with chronic illnesses. These include CHF, COPD and Diabetes.

Concerning Toxicology Testing, AEON Global Health provides accurate and fast quantitative testing of drug metabolite levels in urine and oral fluids. The Company’s testing covers more than 80 analytes and metabolites. Its HPLC-tandem mass spectrometry can analyze wider molecular weight and polarity ranges of analytes, providing better selectivity and sensitivity.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface. Inscrybe® enables physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or via electronic fax instead of transferring paper.

In May 2018, AEON Global Health announced it earned The Joint Commission’s Gold Seal of Approval® for Laboratory Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal of Approval is a symbol of quality, which reflects an organization’s commitment to providing safe and effective patient care.

AEON Global Health underwent a thorough onsite survey earlier in 2018. During the review, a Joint Commission expert surveyor evaluated compliance with laboratory standards related to a number of areas. This included document and process control, healthcare-associated conditions, risk reduction, as well as staff qualifications and competency. Additionally, the surveyor conducted onsite observations and interviews.

AEON Global Health Corp. (AGHC), closed Friday's trading session at $0.168, up 52.7273%, on 1,073 volume with 4 trades. The average volume for the last 3 months is 4,787 and the stock's 52-week low/high is $0.104000002/$0.959999978.

chart

North American Nickel, Inc. (WSCRF)

Stockhouse, OTC Markets, YCharts, and Barchart reported on North American Nickel, Inc. (WSCRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A mineral exploration company, North American Nickel, Inc. is based in Vancouver, British Columbia. The Company has 100 percent owned properties in Maniitsoq, Greenland and Sudbury, Ontario. It mainly explores for nickel, copper, sulphide, platinum group metals, and cobalt deposits. Incorporated in 1983, North American Nickel lists on the OTC Markets Group’s OTCQB.

North American Nickel employs traditional prospecting methods, modern helicopter-borne, ground and borehole geophysical technologies, and state of the art Worldview-3 satellite imaging, detailed mapping, oriented drill core date and 3D modeling to identify targets and target drill holes.

The Company’s Maniitsoq property in Greenland is a Camp scale project. It consists of 2,985 square km covering manifold high-grade nickel-copper sulphide occurrences associated with norite and other mafic-ultramafic intrusions of the Greenland Norite Belt (GNB).

The greater than 75 km-long belt is positioned along, and near, the southwest coast of Greenland. It is accessible from the existing Seqi deep water port with an all year round shipping season and plentiful hydro-electric potential.

The Maniitsoq project is centered roughly 125 km north of Nuuk, the capital of Greenland. It comprises two, contiguous, Mineral Exploration Licences (registration numbers 2011/54 and 2012/28) located just east of the towns of Maniitsoq and Napasoq.

The Post Creek/Halcyon property is in Sudbury, Ontario. It is strategically situated adjacent to the past producing Podolsky copper-nickel-platinum group metal deposit of KGHM International Ltd.

The Post Creek property comprises 39 unpatented mining claims encompassing a region of 912 hectares. The Halcyon property comprises 53 unpatented mining claim units totaling 864 hectares.

Recently, North American Nickel reported that assays were received from seven drill holes and one drill hole extension completed to test targets at Fossilik and the Imiak Hill Complex (IHC) on its 100 percent owned Maniitsoq nickel-copper-cobalt-PGM sulphide project in southwest Greenland. Hole MQ-17-153 intersected numerous zones with elevated nickel values at the P-004 target area within the large Fossilik intrusion.

During the 2017 exploration program, 23 drill holes totaling 8,767 meters were completed to test mineralized zones and geophysical targets in the IHC, Fossilik and P-013 SE areas within the Greenland Norite Belt.

The Fossilik area is in the central portion of the Greenland Norite belt. The Imiak Hill Complex is 8 km north of Fossilik. It consists of the Mikissoq, Imiak Hill and Spotty Hill sulphide zones.

North American Nickel, Inc. (WSCRF), closed Friday's trading session at $0.0285, up 46.1538%, on 275 volume with 1 trade. The average volume for the last 3 months is 5,138 and the stock's 52-week low/high is $0.006/$0.0482.

chart

Premier Holding Corp. (PRHL)

OTC Markets, InvestorsHub, Street Insider, Stockhouse, Investors Hangout, and StockFlare reported on Premier Holding Corp. (PRHL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Premier Holding Corp., by way of its subsidiaries, provides energy efficiency products and services. It does so mainly to commercial middle market companies and residential customers in the U.S. Premier provides financial support and management expertise. This includes access to capital, financing, legal, insurance, mergers, acquisitions, joint ventures (JVs) and management strategies. Listed on the OTCQB, Premier Holding has its corporate office in Tustin, California.

Premier Holding’s companies have wide-ranging experience in technologies and services for deregulated power and expertise in energy reduction. Fundamentally, its companies lower its clients’ price and usage of energy. Premier's mission is to acquire clean technology companies and/or green products and services, which are accretive and that can be seamlessly integrated and use the overall economics of such products and services for the benefit of its customers.

The Company’s holdings include The Power Company and E3 - Energy Efficiency Experts. The Power Company is an experienced energy consulting firm in the deregulation space. It uses its market standing and its large, well-established network of energy suppliers to compete for its clients’ business. The Power Company serves as its clients’ energy advocates. Moreover, it negotiates the most competitive pricing and options for its clients.

The Power Company received the "2017 Leaders Diamond" Award from a major deregulated power supplier. The award combines the volume of sales, connected with the sales of home products. It calculates this with a quality score by customers to create a "Sales Quality" Score. The team at TPC attained the highest score among all resellers for 2017.

E3 - Energy Efficiency Experts is an Energy Services Company (ESCO). E3 was created by Premier Holding to provide the best-of-breed energy reduction solutions for its customers. E3 works to provide the most current, fully-vetted solutions in energy reduction technologies. It also works to provide management tools that capture the client for future opportunities.

Premier Holding has announced that its subsidiary, The Power Company (TPC), supports another large commercial contract. This indicates its breadth of sales into the residential and commercial sectors. TPC continues to help manage and lessen the energy costs for one of the largest and fastest growing physical therapy companies in the nation.

Recently, TPC secured the energy supply for its customer's newest properties in Texas. This helps to manage an important business expense for its customer, while the company continues to expand through organic growth and acquisitions. In addition, this company is in talks to further help reduce its customer's energy costs through the implementation of LED lighting for its locations throughout the country via Premier’s energy efficiency division, E3 - Energy Efficiency Experts.

Premier Holding Corp. (PRHL), closed Friday's trading session at $0.0054, up 50.00%, on 92,272 volume with 8 trades. The average volume for the last 3 months is 46,011 and the stock's 52-week low/high is $0.003599999/$0.019999999.

chart

Validian Corp. (VLDI)

Value Penny Stocks, Epic Stock Picks, Hot Stock Profits, StockMarketIntel, TopPennyStockMovers, Profit Sensation, Stock News Now, Damn Good Penny Picks, Penny Picks, PREPUMP STOCKS, Penny Stock Newsletter, Pumps and Dumps, PennyStocks24, and OTC Stock Review reported previously on Validian Corp. (VLDI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Validian Corp. provides software products for public and private enterprises. In essence, the Company is a top innovator in cyber-security technology. Validian develops and markets solutions to protect against the threats of today's digital world. Validian is first-to-market to provide secure storage, access, and transfer of digital information on wired, wireless, or mobile networks over the Internet. Listed on the OTC Markets Group’s OTCQB, Validian is headquartered in Ottawa, Ontario.

The Company’s technology enables the next generation of secure Cloud Computing, Cloud Storage, Distributed Computing and Web Application and WebPortal Access and Usage for desktop and laptop computers, servers, tablets, and Smartphones. Validian’s products include Validian Protect, which embeds its technology into any application.

Validian provides solutions that can undergo customization to the client's business process to ensure end-to-end authenticity, integrity, and custody of high value digital assets. Validian’s corporate mission is to deliver innovative information protection solutions that help government agencies, enterprises, and individuals in lessening the impact of theft, disclosure, non-compliance, or malicious tampering with digital assets.

The Company has extended its core technology, ValidianProtect. It is now the first cyber security technology to cover and seamlessly protect the Complete Life Cycle of Data with secure access, retrieval, transfer, receipt, storage, and usage of digital information on all devices, operating systems, and technology platforms.

Validian redesigned its ValidianProtect technology to include a group of downloadable, re-usable, feature modules. These make it possible for a programmer to quickly and easily add any combination of a substantial number of pre-built, commonly used functions and first-to-market differentiating features to or from any application, thus saving them numerous man-years of previously extra development time.

In August 2017, Validian announced that it recently completed version 3.3 of its inventive cybersecurity technology. This technology seamlessly protects the Complete Life Cycle of Data on all major technology platforms, operating systems, and devices. This completion consisted of minor modifications in addition to the migration and upgrades already completed to Microsoft Windows 10 and the Azure Cloud platform, as well as to recent versions of Google Android, Apple OS and iOS, and to Red Hat Linux.

Recently, Validian confirmed that some of the large corporations now in talks with Validian concerning strategic partnership agreements are interested in utilizing the Company’s technology to secure and enhance automotive connectivity and communications. This includes vehicle to vehicle communications.

Validian Corp. (VLDI), closed Friday's trading session at $0.02125, up 41.6667%, on 209,386 volume with 17 trades. The average volume for the last 3 months is 400,621 and the stock's 52-week low/high is $0.00575/$0.100000001.

chart

The QualityStocks Company Corner

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $2.97, off by 2.623%, on 82,165 volume with 477 trades. The average volume for the last 3 months is 82,039 and the stock's 52-week low/high is $1.54999995/$5.8499999.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers (TSX.V: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, on Thursday announced that it has received final approval to list its class A subordinated voting shares on the Toronto Stock Exchange (“TSX”). Per the update, the shares will begin trading on the TSX under the ticker symbol “RIV” on September 9 at the opening of markets. The company’s subordinated voting shares will be delisted from the TSX Venture Exchange in conjunction with listing on the TSX. To view the full press release, visit: http://nnw.fm/0DvYp

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Friday's trading session at $1.90, up 7.9545%, on 238,259 volume with 411 trades. The average volume for the last 3 months is 110,485 and the stock's 52-week low/high is $1.60000002/$7.30155992.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) was named today among the upcoming VIC participants. Virtual Investor Conferences and KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, September 12th. REGISTER NOW AT: https://tinyurl.com/0912CannabisVICAgenda  

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Friday's trading session at $3.25, up 3.411%, on 7,299 volume with 33 trades. The average volume for the last 3 months is 34,140 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) operates with the mission of growing the world’s best cannabis and becoming a leader in the global industry. Supreme Cannabis has eyes on the expanding global market and has strategically positioned itself to be a leader in the space, with premium products, authentic brands and international investments. Also today, NetworkNewsWire released a report on the company detailing how SPRWF entered into a definitive agreement to acquire Truverra Inc. in mid-July. A recent article discussing the agreement reads, “The deal involves the transaction of 14.7 million common shares of Supreme Cannabis, with an approximate value of $20,000,000 (http://nnw.fm/5WVLc). To view the full article, visit: http://nnw.fm/20Jca.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Friday's trading session at $1.08, up 2.8571%, on 668,201 volume with 547 trades. The average volume for the last 3 months is 484,313 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope for Cancer Patients.” To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/Bqm4W. To read the full editorial, visit: http://nnw.fm/k9gI7.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Friday's trading session at $0.8924, up 2.5747%, on 13,840 volume with 45 trades. The average volume for the last 3 months is 27,171 and the stock's 52-week low/high is $0.640999972/$2.55999994.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Data and artificial intelligence-driven discovery services company Predictive Oncology (NASDAQ: POAI) provides predictive models of tumor drug response to improve patient outcome. To view the full article, visit: http://nnw.fm/eGbU8.

Predictive Oncology (POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Predictive Oncology (POAI), closed Friday's trading session at $0.4951, up 4.4515%, on 80,780 volume with 199 trades. The average volume for the last 3 months is 44,957 and the stock's 52-week low/high is $0.419999986/$0.850000023.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) was featured today in a report by NetworkNewsWire. Much of the CBD product growth in the coming years will be attributed to the health and wellness niches, where CBD oil is quickly becoming mainstream due to its ability to reduce aches, control inflammation and promote a general sense of wellbeing, as a Forbes report indicates (http://nnw.fm/2ILwD). Also today, the company was featured in the 420 with CNW by CannabisNewsWire. While Colombia has been infamous as a major player in the illegal drugs trade due to its production of illicit marijuana and cocaine, the country is slowly but steadily making its mark as a major player on the international market for medical marijuana, according to the British Broadcasting Corporation (BBC).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Friday's trading session at $0.351, up 6.3636%, on 7,197 volume with 5 trades. The average volume for the last 3 months is 16,482 and the stock's 52-week low/high is $0.250999987/$1.12999999.

Recent News

chart

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: IONKF).

IONIC Brands (CSE: IONC) (OTC: IONKF) (FRA: IB3) recently acquired Vegas Valley Growers North (“VVG”), a Las Vegas, Nevada, state-licensed cultivation and manufacturing firm (http://nnw.fm/ujZm3). To view the full article, visit: http://nnw.fm/2adOo.

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in leading markets across the western United States, with current operations in Washington, Oregon, California and Nevada. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC’s product lines are pioneering the changing landscape of cannabis consumption. The company’s refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC’s Certified Clean program verifies that every product leaving the company’s facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green’s technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package’s QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company’s flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC’s immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC’s expansion and development into Washington state’s leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck’s.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC’s aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the “Top 50 Companies to Work for in Cannabis” by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: IONKF), closed Friday's trading session at $0.10, up 11.8568%, on 293,782 volume with 65 trades. The average volume for the last 3 months is 262,550 and the stock's 52-week low/high is $0.035999998/$0.634559988.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade (OTCQB: SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, currently holds a strong position as American farmers pursue refuge from the low prices and decreased sales created by the ongoing U.S.-China trade war. To view the full article, visit: http://nnw.fm/8ZWrZ.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed Friday's trading session at $0.0117, up 2.6316%, on 1,445,520 volume with 66 trades. The average volume for the last 3 months is 5,134,200 and the stock's 52-week low/high is $0.00975/$0.164000004.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Trxade Group (OTCQB: TRXD), an integrated pharmaceutical services company, is focused on supporting independent and community-based small pharmacies through its innovative, web-based purchasing platform. To view the full article, visit: http://nnw.fm/3Bxq0

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed Friday's trading session at $1.00, even for the day, on 3,559 volume with 13 trades. The average volume for the last 3 months is 5,957 and the stock's 52-week low/high is $0.230000004/$1.20000004.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) announces the availability of a NetworkNewsAudio publication titled, “Innovative Drug-Delivery Systems Benefit Patients and Businesses.” To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/J4u6k. To read the full editorial, visit: http://nnw.fm/4P2sn.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Friday's trading session at $0.68, even for the day, on 21,348 volume with 40 trades. The average volume for the last 3 months is 80,087 and the stock's 52-week low/high is $0.600000023/$2.20000004.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly" or the “Company”) is pleased to announce the appointment of Constantine Constandis, an independent Director, to the Board of Directors.

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed Friday's trading session at $0.3092, off by 2.7673%, on 410,922 volume with 93 trades. The average volume for the last 3 months is 199,533 and the stock's 52-week low/high is $0.189099997/$0.850000023.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings Inc. (CSE:NAB) (OTC: NABIF) (FRA: A2PL) (“Nabis™” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced that Kevin Ma has resigned from the Company’s Board of Directors, effective September 6, 2019, in order to focus on other business obligations. Mr. Ma will continue to perform consulting services for Nabis.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Friday's trading session at $0.09, off by 11.7647%, on 53,815 volume with 26 trades. The average volume for the last 3 months is 64,351 and the stock's 52-week low/high is $0.0898/$0.791499972.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands, LP (VPRB) was featured today in the 420 with CNW by CannabisNewsWire. Currently, Colombia has a number of farms that are dedicated to cultivating medical marijuana for the export market.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit www.goldlinehemp.com for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Friday's trading session at $0.0731, off by 18.7778%, on 290,188 volume with 22 trades. The average volume for the last 3 months is 205,281 and the stock's 52-week low/high is $0.033799998/$0.119999997.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.